Indian obesity pharma market is in a dramatic change with the records being broken by Eli Lilly’s Mounjaro (tirzepatide) going over ₹100 crore in sales in only four months of launch in March 2025.
The speed of adoption reveals an increasing need for effective, low-cost weight-loss drugs as India witnesses an increase in obesity and type 2 diabetes.
Introduction: Why Mounjaro Is Shaping India’s Obesity Treatment Landscape
Obesity is a rising health issue in India, with few available therapeutic choices. Mounjaro is an injectable medication that functions as a dual GIP and GLP1 receptor agonist, offering a revolutionary solution that treats weight loss as well as blood sugar management effectively. Through July 2025, Mounjaro received overwhelming support from healthcare professionals and patients alike, as seen through rocketing sales and outpacing competitors in volume.
Mounjaro’s Emergence in India’s Weight Loss Industry
What is Mounjaro and How is it Different?
Mounjaro uses two mechanisms: activation of GIP (glucosedependent insulinotropic polypeptide) and GLP1 (glucagonlike peptide1) receptors which results in:
- Greater weight loss efficacy compared to GLP1 alone drugs
- Potent appetite suppression and better glycemic control
- Cardiovascular benefits, lowering risks of heart failure and kidney disease
- A lower price tag in the Indian market than competitors such as Wegovy (semaglutide)
Sales and Market Penetration Highlights
- Attained ₹98–100 crore worth of total sales in four months (March to July 2025)
- Registered ₹47 crore in sales for the month of July alone, up from ₹23 crore in June
- Sold around 1,57,000 units in July, largely outselling Wegovy’s ~5,000 units in July
- Projected revenues would surpass ₹500 crore by March 2026 if the current growth rate persists
Also read :
India’s Growing Obesity Drug Market & Biotech Trends
Overview of Market Growth
- India’s antiobesity drug market increased from ₹133 crore in 2021 to ₹628 crore as of mid 2025
- GLP1 receptor agonists, particularly Mounjaro and semaglutide, lead this growing market
- Indian generic drug manufacturers are gearing up for patent losses (most notably semaglutide in 2026), which can bring in generics and lower prices, making it more accessible
Trends in Injectable Weight Loss Therapies
- Injectable therapies are used in preference due to their greater efficacy compared to oral drugs
- Dual agonist medications such as Mounjaro increase both weight loss and glycemic control
- Doctors are embracing these newer treatments quickly due to their clinical advantages and better patient outcomes
Mounjaro vs Ozempic and Wegovy in India: Competitive Strengths
| Feature | Mounjaro (Tirzepatide) | Wegovy (Semaglutide) | Ozempic (Semaglutide) |
| Mechanism | Dual GIP + GLP1 agonist | GLP1 receptor agonist | GLP1 receptor agonist |
| Weight Loss Efficacy | Higher | Moderate | Moderate |
| Cardiovascular Benefits | Substantial | Moderate | Moderate |
| India Price | Lower | Higher | Higher |
| Sales Volume (July 2025) | ~1,57,000 units | ~5,000 units | Less than Mounjaro but increasing |
Mounjaro’s two way mechanism, efficacy, and low pricing have catapulted it ahead of Wegovy in terms of prescriptions and sales volume in India.
Frequently asked question :
Q1: How rapidly is Mounjaro’s popularity growing in India?
Since its launch in March 2025, Mounjaro’s sales volume increased 15fold by July, with monthly revenues doubling consistently to ₹47 crore in July alone.
Q2: Is Mounjaro safe and effective for longterm use?
Clinical trials reveal substantial weight loss, enhanced blood sugar control, and cardiovascular benefits, making it effective for chronic obesity and type 2 diabetes management.
Q3: How does Mounjaro compare to other weight loss drugs in India?
Mounjaro has more effective weight loss and superior cardiometabolic benefits compared to semaglutideonly therapies like Wegovy, with better pricing.
Q4: Will generics impact Mounjaro’s market share?
Though generic versions of semaglutide drugs are likely following patent expiry in 2026, Mounjaro’s dual agonist profile is expected to maintain high demand.
Conclusion: Mounjaro Sets a New Benchmark in India’s Obesity Treatment
Mounjaro’s meteoric rise to ₹100 crore sales in four months is a milestone achievement for India’s diabetes and obesity treatment industries. The drug’s intense efficacy, cardiovascular advantages, and affordability signal India’s pressing demand for improved weight management therapies. With the evolving market, Mounjaro is set to continue as a leading player, an affirmation of increasing patient confidence and redrawing India’s landscape for obesity drugs.
Key Takeaways
- Mounjaro crossed more than ₹100 crore in sales in a mere four months of its India debut, reflecting unprecedented market acceptance.
- It is a dual GIP and GLP1 receptor agonist, offering more weight reduction and cardiovascular advantages than GLP1only agents.
- July 2025 sales volume (~1,57,000 units) far exceeded the likes of Wegovy (~5,000 units), indicating robust physician and patient favor.
- The Indian market for obesity drugs increased from ₹133 crore in 2021 to ₹628 crore in 2025 with injectable treatments and dual agonists dominating the trend.
- Mounjaro’s low cost of treatment in India and excellent clinical success have powered its tremendous growth.
- Semaglutide generics are expected to hit the market in 2026, increasing competition in the market, but a unique mechanism of action for Mounjaro probably guarantees that it will continue to attract demand.
- This expansion indicates increased awareness and demand for efficient, cost effective obesity therapies in India’s vibrant biotech and pharma industries.
Reference:
Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 months – The Economic Times
Leave a Reply